Skip to main content
Erschienen in: Virchows Archiv 3/2012

01.03.2012 | Original Article

Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach

verfasst von: Tina Zahel, Sabine Krysa, Esther Herpel, Albrecht Stenzinger, Benjamin Goeppert, Peter Schirmacher, Hans Hoffmann, Philipp A. Schnabel, Arne Warth

Erschienen in: Virchows Archiv | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary carcinoids (PC) are separated into typical (TC) and atypical carcinoids (ATC). However, the biological behavior cannot be reliably predicted, and in small biopsies differential diagnosis can be challenging. To provide a basis for a grading approach, we analyzed mitoses and the proliferative index (PI; Ki-67) of 200 PC specimens (TC: n = 114; ATC: n = 86). To define suitable diagnostic and to screen for putative therapeutic markers, CD56, CD57, CD99, CD117, TTF-1, synaptophysin, chromogranin A, CK 18, KL-1, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her-2/neu), somatostatin receptor subtype 2A (SSTR2A), thymidylate synthase (TS), and excision repair cross-complementation group 1 (ERCC-1) expression was analyzed. A combination of synaptophysin and cytokeratins is the most sensitive marker panel for PC with unclear histomorphology. Predictive phenotyping revealed that SSTR2A is expressed in >80% of all PC and may be used both, as a diagnostic marker for imaging approaches and as a predictive marker for octreotide-based therapies. We introduced a grading system distinguishing between PC with low and highly aggressive biological behavior similar to the grading system for gastrointestinal neuroendocrine tumors. The system is superior to the classical separation into TC and ATC. This study indicates that PI in addition to mitotic count may improve prediction of the biological behavior of PC and should be validated in prospective studies.
Literatur
2.
Zurück zum Zitat Travis WD (ed) (2004) WHO classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart, 1st edn. IARC, Lyon Travis WD (ed) (2004) WHO classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart, 1st edn. IARC, Lyon
4.
Zurück zum Zitat Warth A, Herpel E, Krysa S, Hoffmann H, Schnabel PA, Schirmacher P, Mechtersheimer G, Blaker H (2009) Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 41(5):349–353. doi:10.3858/emm.2009.41.5.039 PubMedCrossRef Warth A, Herpel E, Krysa S, Hoffmann H, Schnabel PA, Schirmacher P, Mechtersheimer G, Blaker H (2009) Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 41(5):349–353. doi:10.​3858/​emm.​2009.​41.​5.​039 PubMedCrossRef
5.
Zurück zum Zitat Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, Wihlm JM (1998) Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 65(5):1410–1414. doi:S0003497598000836 PubMedCrossRef Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, Wihlm JM (1998) Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 65(5):1410–1414. doi:S000349759800083​6 PubMedCrossRef
6.
Zurück zum Zitat Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA (1985) Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 89(6):819–825PubMed Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA (1985) Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 89(6):819–825PubMed
7.
Zurück zum Zitat Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119(6):1647–1651PubMedCrossRef Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119(6):1647–1651PubMedCrossRef
9.
Zurück zum Zitat Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM (2003) Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 10(6):697–704PubMedCrossRef Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM (2003) Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 10(6):697–704PubMedCrossRef
10.
Zurück zum Zitat Warth A, Krysa S, Zahel T, Hoffmann H, Schirmacher P, Schnabel PA, Herpel E (2010) S100 protein positive sustentacular cells in pulmonary carcinoids and thoracic paragangliomas: differential diagnostic and prognostic evaluation. Pathologe 31(5):379–384. doi:10.1007/s00292-010-1293-2 PubMedCrossRef Warth A, Krysa S, Zahel T, Hoffmann H, Schirmacher P, Schnabel PA, Herpel E (2010) S100 protein positive sustentacular cells in pulmonary carcinoids and thoracic paragangliomas: differential diagnostic and prognostic evaluation. Pathologe 31(5):379–384. doi:10.​1007/​s00292-010-1293-2 PubMedCrossRef
11.
12.
Zurück zum Zitat Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401. doi:10.1007/s00428-006-0250-1 PubMedCrossRef Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401. doi:10.​1007/​s00428-006-0250-1 PubMedCrossRef
13.
Zurück zum Zitat Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22(8):934–944PubMedCrossRef Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22(8):934–944PubMedCrossRef
14.
Zurück zum Zitat Skuladottir H, Hirsch FR, Hansen HH, Olsen JH (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37(2):127–135PubMedCrossRef Skuladottir H, Hirsch FR, Hansen HH, Olsen JH (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37(2):127–135PubMedCrossRef
15.
Zurück zum Zitat Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O’Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(3):300–313. doi:10.1097/PAS.0b013e3181ce1447 PubMedCrossRef Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O’Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(3):300–313. doi:10.​1097/​PAS.​0b013e3181ce1447​ PubMedCrossRef
16.
Zurück zum Zitat Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV (2001) Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 25(6):815–819PubMedCrossRef Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV (2001) Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 25(6):815–819PubMedCrossRef
17.
Zurück zum Zitat Folpe AL, Gown AM, Lamps LW, Garcia R, Dail DH, Zarbo RJ, Schmidt RA (1999) Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 12(1):5–8PubMed Folpe AL, Gown AM, Lamps LW, Garcia R, Dail DH, Zarbo RJ, Schmidt RA (1999) Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 12(1):5–8PubMed
18.
Zurück zum Zitat Sturm N, Rossi G, Lantuejoul S, Papotti M, Frachon S, Claraz C, Brichon PY, Brambilla C, Brambilla E (2002) Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33(2):175–182PubMedCrossRef Sturm N, Rossi G, Lantuejoul S, Papotti M, Frachon S, Claraz C, Brichon PY, Brambilla C, Brambilla E (2002) Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33(2):175–182PubMedCrossRef
19.
Zurück zum Zitat Du EZ, Goldstraw P, Zacharias J, Tiffet O, Craig PJ, Nicholson AG, Weidner N, Yi ES (2004) TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 35(7):825–831PubMedCrossRef Du EZ, Goldstraw P, Zacharias J, Tiffet O, Craig PJ, Nicholson AG, Weidner N, Yi ES (2004) TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 35(7):825–831PubMedCrossRef
20.
Zurück zum Zitat La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457(4):497–507. doi:10.1007/s00428-010-0954-0 PubMedCrossRef La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457(4):497–507. doi:10.​1007/​s00428-010-0954-0 PubMedCrossRef
21.
Zurück zum Zitat Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762. doi:10.1007/s00428-007-0452-1 PubMedCrossRef Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762. doi:10.​1007/​s00428-007-0452-1 PubMedCrossRef
22.
Zurück zum Zitat Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198(3):292–299. doi:10.1002/path.1218 PubMedCrossRef Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198(3):292–299. doi:10.​1002/​path.​1218 PubMedCrossRef
24.
Zurück zum Zitat Dhall D (2009) Interobserver variability in assessing Ki67 proliferative index in gastrointestinal well-differentiated neuroendocrine neoplasms. Mod Pathol 22:116A Dhall D (2009) Interobserver variability in assessing Ki67 proliferative index in gastrointestinal well-differentiated neuroendocrine neoplasms. Mod Pathol 22:116A
25.
26.
Zurück zum Zitat Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol 21(3):548–555. doi:10.1093/annonc/mdp334 PubMedCrossRef Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol 21(3):548–555. doi:10.​1093/​annonc/​mdp334 PubMedCrossRef
27.
Zurück zum Zitat Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182. doi:10.1038/modpathol.3800954 PubMedCrossRef Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182. doi:10.​1038/​modpathol.​3800954 PubMedCrossRef
28.
Zurück zum Zitat Rusch VW, Klimstra DS, Venkatraman ES (1996) Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 62(3):798–809, discussion 809-710PubMedCrossRef Rusch VW, Klimstra DS, Venkatraman ES (1996) Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 62(3):798–809, discussion 809-710PubMedCrossRef
30.
Zurück zum Zitat Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4):1059–1064. doi:10.1158/1078-0432.CCR-07-1513 PubMedCrossRef Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4):1059–1064. doi:10.​1158/​1078-0432.​CCR-07-1513 PubMedCrossRef
31.
Zurück zum Zitat Oberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 30(4):503–507PubMedCrossRef Oberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 30(4):503–507PubMedCrossRef
33.
Zurück zum Zitat Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77(4):632–637PubMedCrossRef Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77(4):632–637PubMedCrossRef
34.
Zurück zum Zitat Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9):1349–1356. doi:10.2967/jnumed.110.075002 PubMedCrossRef Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9):1349–1356. doi:10.​2967/​jnumed.​110.​075002 PubMedCrossRef
35.
Zurück zum Zitat Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59(5):637–642. doi:10.1007/s00280-006-0306-6 PubMedCrossRef Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59(5):637–642. doi:10.​1007/​s00280-006-0306-6 PubMedCrossRef
37.
38.
Zurück zum Zitat Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9):1534–1539. doi:10.1200/JCO.2009.25.9275 PubMedCrossRef Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9):1534–1539. doi:10.​1200/​JCO.​2009.​25.​9275 PubMedCrossRef
Metadaten
Titel
Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach
verfasst von
Tina Zahel
Sabine Krysa
Esther Herpel
Albrecht Stenzinger
Benjamin Goeppert
Peter Schirmacher
Hans Hoffmann
Philipp A. Schnabel
Arne Warth
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 3/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-012-1194-2

Weitere Artikel der Ausgabe 3/2012

Virchows Archiv 3/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie